Skip to main content
Premium Trial:

Request an Annual Quote

Aclara Posts Uptick in Q2 Revenues as Losses Decrease; Acquisition By Virologic Still On

NEW YORK, Aug. 6 (GenomeWeb News) - Aclara Biosciences on Wednesday reported an uptick in second-quarter revenue amid significantly decreased R&D spending and a narrowed net loss.

 

The company, which is slated to be acquired by ViroLogic during the fourth quarter, generated $515,000 in receipts for the three months ended June 30 compared with $405,000 in the year-ago quarter.

 

Second-quarter R&D spending shrank to $2.7 million from $4 million year over year.

 

Largely as a result, net loss decreased to $4.9 million, or $.13 per share, from $5.1 million, or $.14 per share, during the second quarter last year.

 

Aclara, based in Mountain View, Calif., said it had around $81.9 million in cash, equivalents, and marketable securities as of June 30.

 

Click here for more information.

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.